TRAF4 is an adapter protein overexpressed in certain cancers but its contributions to tumorigenesis are unclear. In lung cancer cells and primary lung tumors, we found that TRAF4 is overexpressed. RNAi-mediated attenuation of TRAF4 expression blunted the malignant phenotype in this setting, exerting inhibitory effects on cell proliferation, anchorage-independent growth and tumor development in a xenograft mouse model. Unexpectedly,we discovered that TRAF4, but not Skp2, was required for activation of the pivotal cell survival kinase Akt through ubiquitination. Furthermore, TRAF4 attenuation impaired glucose metabolism by inhibiting expression of Glut1 and HK2 mediated by the Akt pathway. Overall, our work suggests that TRAF4 offers a candidate molecular target for lung cancer prevention and therapy.
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Précis
Findings reveal a pivotal role for a ubiquitylation enzyme in Akt control and lung cancer pathophysiology, suggesting its role as a candidate molecular target for lung cancer prevention and therapy.
Introduction
Lung cancer is the leading cause of cancer-related death in the world (1) . Although advanced molecular biology techniques have greatly accelerated the understanding of the biological mechanisms that underlie lung cancer development, the 5-year survival rate is 15%, which has hardly improved from the 13% reported 35 years ago (2, 3) . A major challenge in treating lung cancer is to identify novel therapeutic targets that can complement current chemotherapy (4) .
Akt signaling plays a major role in tumorigenesis by regulating cell proliferation, cell cycle, cell survival and metabolism (5) (6) (7) . Akt is constitutively activated in lung cancer, where it can regulate cancer cell growth and survival and confer resistance to chemotherapy or radiation treatment (8, 9) . It is activated by various stimuli, including insulin and EGF, and Akt phosphorylation at Thr308 by PDK1 and at Ser473 by mTORC2 is required for full activation (10) . Studies detailing Akt activation indicate that Lys63-mediated ubiquitination is essential for Akt activity (11, 12) . Notably, different stimuli utilize distinct E3 ligases for Akt ubiquitination.
For example, TRAF6 or Skp2 mediates Akt activation through ubiquitination in IGF-1 or ErbB receptor signaling, respectively (13, 14) . Additionally, Akt hyperactivation as a consequence of Skp2 overexpression drives abnormal glycolysis in breast cancer, and Skp2 is a marker for poor prognosis in HER2-positive patients (14) .
TRAF4 is an atypical TRAF family member. Unlike other TRAFs, which are not relevant to the genetic phenotype, in vivo evidence strongly suggests that TRAF4 is involved in embryogenesis (15) and central nervous system myelin homeostasis (16) (17) . Furthermore, TRAF4 deficiency results in severe developmental changes in the respiratory system, axial skeleton and nervous system (17, 18) . TRAF4 was first identified by differential screening of human metastatic lymph nodes from a breast cancer cDNA library (19) . The amplification and overexpression of TRAF4 suggested that it was involved in the initiation and progression of primary breast cancers and metastases (19) (20) (21) . Although TRAF4 is overexpressed in various human malignancies (22) , the mechanism regarding TRAF4's role in tumorigenesis remains unclear.
In the present study, we found that TRAF4 plays an important role in lung tumorigenesis.
Knockdown of TRAF4 dramatically attenuated the malignant phenotype in lung cancer, including proliferation, anchorage-independent growth and tumor formation ability in nude mice.
Furthermore, we demonstrated that TRAF4, but not Skp2, is required for EGF-induced Akt activation through its ubiquitination in lung cancer. TRAF4 deficiency markedly impaired the activity of Akt signaling and Akt-mediated lung cancer glycolysis.
Materials and Methods
Reagents and Antibodies. Tris, NaCl, and SDS for molecular biology and buffer preparation were purchased from Sigma (St. Louis, MO). Cell culture media and supplements were from Invitrogen (Grand Island, NY). Antibodies against phosphorylated Akt (Ser473 or Thr308), Akt1, panAkt, phosphorylated S6 (Ser235/236), S6, HK2 and ubiquitin (P4D1) were obtained from Cell Signaling Technology, Inc. (Beverly, MA). Antibodies against TRAF4, TRAF6, β-actin, α-tubulin, Flag-tag, Myc-tag and HA-tag were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-Flag-HRP was from Sigma. The Glut1 antibody was obtained from Millipore (Billerica, MA) and anti-E-cadherin was from BD Biosciences (San Jose, CA). Burlingame, CA) was used for immunohistochemical staining according to the recommended protocol. Briefly, the slide was baked at 60 °C for 2 h, deparaffinized, and rehydrated. To expose antigens, the slide was unmasked by submersion into boiling sodium citrate buffer (10 mM, pH 6.0) for 10 min, and then treated with 3% H 2 O 2 for 10 min. The slide was blocked with 50% goat serum albumin in 1×PBS in a humidified chamber for 1 h at room temperature and then with a TRAF4 antibody (1:100 dilution in 50% goat serum with PBS) at 4 °C in a humidified chamber Ubiquitination Assays. In vitro ubiquitination assays were performed as described (14) . Briefly, were diluted in RIPA buffer and supernatant fractions were pre-cleared with Protein A/G beads for 2 h, and immunoprecipitated overnight with anti-Flag or anti-Akt, after which Protein A/G beads were added for an additional 2 h. Beads were centrifuged and washed 4x with E1A Buffer.
Proteins were eluted in 6×SDS sample buffer and subjected to immunoblotting.
Statistical analysis. All quantitative data are expressed as mean values ± S.D of at least 3 independent experiments. Significant differences were determined by Student's t test or by oneway ANOVA. A probability value of p < 0.05 was used as the criterion for statistical significance.
Results

TRAF4 is overexpressed in human lung cancer.
Clinical RNA database sequence analysis of 40 lung cancer patients revealed overexpression of TRAF4 (data not shown). To verify the high expression of TRAF4 in lung cancer, we determined the protein level of TRAF4 in different lung cancer cell lines and in a human lung cancer tissue array. Results showed that, compared with normal MRC5 lung cells or normal tissue, TRAF4 is overexpressed in lung cancer cells (Fig. 1A) and in lung cancer tissues (Fig. 1B) . These results indicated that TRAF4 might be a critical molecule in lung cancer development.
TRAF4 has a critical role in cell transformation. To investigate TRAF4 function in lung cancer, we generated TRAF4 knockdown stable HaCaT cells using two different sh-TRAF4 sequences ( Fig. 2A, left top ). An anchorage-independent growth assay was performed to assess the effect of TRAF4 on cell transformation. The result indicated that EGF-induced colony 
formation was attenuated in TRAF4 knockdown cells ( Fig. 2A, right, lower) . Furthermore, overexpression of TRAF4 promoted anchorage-dependent growth (Fig. 2B, lower) and increased anchorage-independent growth with EGF treatment (Fig. 2C, upper) . Usually, without EGF, HaCaT cells cannot form colonies but, unexpectedly, colony formation was observed in HaCaT cells overexpressing TRAF4 even without EGF treatment (Fig. 2C, lower) . Furthermore, although TRAF4 alone could not transform 3T3 cells, it dramatically promoted the transformation ability of H-RasG12V (Fig. 2D) . These results suggested that TRAF4 is associated with cell transformation.
Knockdown TRAF4 in human lung cancer cells reduces tumorigenic properties. Based on our observations, we hypothesized that TRAF4 may affect the tumorigenic properties in lung cancer. Thus, we generated stable knockdown TRAF4 A549 (Fig. 3A, upper) and H460 (Fig. 3B, left) cells and measured anchorage-dependent growth. Results showed that knockdown TRAF4 inhibited proliferation of A549 (Fig. 3A, lower) or H460 cells (Fig. 3B, right) . Knocking down TRAF4 expression also suppressed anchorage-independent growth of A549 (Fig. 3C) and H460 ( Fig. 3D ) lung cancer cells. We extended our study to examine an additional 5 lung cancer cell lines, including H520, HCC827, H1650, H1299 and H1975 cells. Results indicated that knockdown TRAF4 inhibited proliferation and anchorage-independent growth of all lung cancer cell lines examined (Fig. S1) . Furthermore, we found that xenograft growth of A549 cells in athymic nude mice was also attenuated after TRAF4 knockdown (Fig. 3E) . These results suggest that blocking TRAF4 expression significantly reduces the tumorigenic properties of lung cancer cells. 
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TRAF4 is required for Akt activation and recruitment to the membrane. Unlike other TRAF family members, TRAF4 has not yet been clearly associated with a specific receptor or signaling pathway. To examine the function of TRAF4 in EGF signaling, we assessed the activation of the EGF pathway in knockdown TRAF4 HaCaT cells treated with EGF. Results showed that knocking down TRAF4 expression impaired Akt phosphorylation and its downstream kinase S6 (Fig. 4A, left) and overexpression of TRAF4 promoted phosphorylation of Akt and S6 (Fig. 4A, right) with EGF treatment. We also investigated the effect of TRAF4 on EGF signaling in lung cancer cells. Indeed, TRAF4 knockdown strikingly inhibited EGFinduced Akt signaling in A549 (Fig. 4B ) and H460 (Fig. 4C ) lung cancer cells. Recruitment of Akt to the cell membrane is critical for Akt activation. We next investigated whether knockdown of TRAF4 affected Akt membrane translocation. Results showed that TRAF4 is not only found in the cytoplasm, but is also expressed on the cell membrane. In shMock cells, EGF treatment induced Akt membrane translocation and activation; and phosphorylation of Akt on both Thr308 and Ser473 was dramatically up-regulated after EGF stimulation. However, knockdown of TRAF4 inhibited EGF-induced Akt membrane recruitment, which corresponded with a decrease in phosphorylation of Akt on both Thr308 and Ser473 (Fig. 4D) . Immunofluorescence staining results showed that Akt membrane translocation induced by EGF stimulation was inhibited in TRAF4 knockdown cells (Fig. S2) .
Because E3 ligase TRAF6 and Skp2 are important for growth factors IGF-1 and EGFinduced Akt ubiquitination and activation (13, 14) , respectively, we further determined whether EGF-induced Akt activation and membrane recruitment depend on TRAF6 in lung cancer. As was expected, EGF-induced Akt activation in A549 (Fig. S3A) and H460 (Fig. S3B) shMock and shTRAF6 cells, which is consistent with a previous study reporting that TRAF6 is unnecessary for EGF-induced Akt activation (14) . Next, we wanted to know whether Skp2 or TRAF4 is most important for EGF-induced Akt activation in lung cancer. Thus, we compared the level of TRAF4, Skp2 and Akt phosphorylation in 8 lung cancer cell lines and one normal lung cell line. Unexpectedly, unlike TRAF4 that is highly expressed in lung cancer cells, compared to normal lung cells, Skp2 exhibited a relatively similar, low expression level in all of the lung cancer cell lines examined. Additionally, the TRAF4 high expression was accompanied by Akt hyperphosphorylation (Fig. S4A) . Moreover, knockdown of Skp2 in lung cancer cells had no effect on EGF-induced Akt activation (Fig. S4B) , which suggested that TRAF4, but not Skp2, is required for Akt activation in lung cancer.
TRAF4 interacts with Akt1. To investigate the mechanism explaining how TRAF4 regulates
Akt activity, we first studied the interaction between TRAF4 and Akt1. Flag-TRAF4 and HAAkt1 were co-transfected into 293T cells and immunoprecipitated with anti-Flag or anti-HA to detect HA-Akt1 or Flag-TRAF4 in the IP complex (Fig. 5A ). In addition, the endogenous Akt1 and TRAF4 interaction was observed in A549 (Fig. 5B ) and HaCaT cells ( interaction between TRAF4 and Akt1 (Fig. 5D) . We also showed that the TRAF4 Ring domain or TRAFc domain deletion mutant lost the ability to promote cell transformation (Fig. S5C, D) .
Collectively, our data demonstrated that TRAF4 binds with Akt1 through the TRAFc domain and its physiological function relies on the Ring and TRAFc domains.
TRAF4 is required for Akt1 Ub-Lys63 ubiquitination.
Previous results showed that TRAF4 is required for recruitment of Akt to the cell membrane for its activation. Because TRAF4 interacts with Akt (Fig. 5) , we hypothesized that TRAF4 might function as an E3 ligase to mediate Akt activation through ubiquitination. Indeed, TRAF4 overexpression induced Akt1 Ub-Lys63 mediated ubiquitination in 293T cells (Fig. 6A) . Notably, we found that knockdown of TRAF4 abrogated EGF-induced Akt ubiquitination in A549 cells (Fig. 6B ). Ubc13 is a well-known E2 ubiquitin-conjugating enzyme and is required for E3 ligase activity, including TRAF2 and TRAF6 mediated Ub-Lys63 ubiquitination (24, 25) . To investigate whether TRAF4 has a potential E3 ligase activity, an in vitro ubiquitination assay was performed. The result showed that Ubc13 together with TRAF6 induced Akt1 ubiquitination and TRAF6 auto-ubiquitination.
However, Ubc13 is not available for TRAF4-induced Akt1 ubiquitination (Fig. 6C) . Instead, we observed that another E2 ubiquitin-conjugating enzyme, UbcH5a (26, 27) , is suitable for TRAF4-induced Akt1 ubiquitination in vitro (Fig. 6D) . Importantly, we also noticed that the knockdown of Akt1 (Fig. S6A) inhibited HaCaT cell proliferation (Fig. S6B) and EGF-induced neoplastic transformation (Fig. S6C) . We also observed a similar impairment in cell proliferation and colony formation ability in various types of human lung cancer cells, including H1650, H1299, A549 and H460 cells (Fig. S7A-D) . These results indicate that TRAF4 might possess an E3 ligase activity and is required for Akt1 ubiquitination.
TRAF4 regulates lung cancer cellular glycolysis that is dependent on Akt activity. The Akt signaling pathway is a hub in the regulation of cancer metabolism (28) . We speculated that TRAF4 might be involved in the regulation of lung cancer cellular glucose metabolism. Indeed, we observed that knockdown of TRAF4 inhibited the expression of Glut1 and HK2 (Fig. 7A, B, left), and also attenuated glucose uptake (Fig. 7A, B , middle) and lactate production (Fig. 7A, B, right) in both A549 and H460 lung cancer cells. The inhibitory effect on glucose metabolism induced by knocking down TRAF4 expression was not a result of differences in cell numbers (Fig. S8A, B) . In order to further determine whether the regulation of glycolysis by TRAF4 is dependent on Akt activity, we transfected constitutively activated Akt1 (CA-Akt1) into knockdown TRAF4 stable A549 and H460 cells. CA-Akt1 transfection up-regulated Glut1 and HK2 expression (Fig. 7C, D, left) . Moreover, CA-Akt1 rescued the deficient glucose uptake (Fig.   7C , D, middle) and lactate production (Fig. 7C, D, right) in TRAF4 knockdown lung cancer cells.
These results suggest that TRAF4 regulates glycolysis in human lung cancer cells, and these biochemical processes are partly mediated by TRAF4 modulation of Akt activation. 
TRAF4 was initially identified in human breast carcinoma in 1995 (19) . Previous studies revealed that TRAF4 is engaged in several signaling pathways. For instance, TRAF4 binds with MEKK4 to regulate JNKs activation (29) and also interacts with NOD2 to inhibit innate immune responses (30, 31) . TRAF4 plays a role in restricting IL-17 signaling and Th17-mediated disease (32) . TRAF4 mediates GITR-induced NF-κB activation (33) and TRAF4 can localize on the membrane to regulate cellular adherent junctions (34) . Although TRAF4 is highly expressed in human carcinomas (22) , its biological functions in tumorigenesis remain unclear.
Our results showed that TRAF4 is overexpressed in human lung cancer cell lines and tissues. To study the function of TRAF4, we generated a stable TRAF4 knockdown HaCaT cell line and TRAF4 knockdown attenuated EGF-induced transformation ( Fig. 2A) . TRAF4 overexpression promoted EGF-induced cell transformation and even without EGF, TRAF4 overexpression induced anchorage-independent growth of HaCaT cells (Fig. 2C ). Additionally, TRAF4 enhanced H-RasG12V-induced 3T3 cell transformation (Fig. 2D) . Furthermore, we demonstrated that TRAF4 is required for the malignant phenotype of human lung cancer cells, including proliferation, colony growth in soft agar, and the ability to form tumors in athymic nude mice (Fig. 3, S1 ). These results suggested that TRAF4 plays an important role in human lung carcinogenesis. However, a prior study identified TRAF4 as a p53-regulated pro-apoptotic gene in a p53 temperature-sensitive cell line Vm10 (23) . TRAF4 overexpression in p53 wildtype tumor cells, U2OS and HCT116, induced apoptosis and inhibited colony formation (23) . This apparent discrepancy suggests that the same gene can display various biological functions that are dependent upon the form of stimulation and cell type. 
ERKs and PI3K-Akt pathways, which notably accelerate malignant progression and induce drug resistance (35) (36) (37) . We found that TRAF4 knockdown impaired EGF-induced Akt activation (Fig. 4A-C) , but had no effect on EGFR or ERK1/2 activity (data not shown). Our results revealed that EGF-induced Akt membrane recruitment was decreased in TRAF4 knockdown lung cancer cells (Fig. 4E, S2) . These results led us to conclude that TRAF4 is involved in regulating the Akt signaling pathway.
Recent studies indicated that Lys63-linked ubiquitination of Akt is critical in the process of Akt membrane recruitment and activation in response to growth factors (11, 13, 14) . In addition, TRAF2 reportedly regulates RSK2 activation through Lys63-linked ubiquitin in EGF signaling (38) . Consistent with structural characteristics of other TRAF protein family members, TRAF4 has an N-terminal Ring domain followed by a series of zinc fingers. The Ring domain of TRAF proteins confers E3 ubiquitin ligase capability (39) . However, only two TRAF family members, TRAF6 (40) and TRAF2 (41) , were demonstrated to possess E3 ligase activity. We found that TRAF4 binds with Akt1 through the C-terminal TRAFc domain, and importantly, this binding was also enhanced by EGF treatment (Fig. 5) . Moreover, this is the first report to show that TRAF4 is required for Akt ubiquitination (Fig. 6) . We examined the role of Skp2 in EGFtriggered Akt ubiquitination and activation in human lung cancer. Unexpectedly, Skp2 expression was not different in human lung cancer cells compared with normal lung cells.
Notably, knockdown of Skp2 had no effect on EGF-induced Akt activation (Fig. S4) . Our results imply that TRAF4, and not Skp2, is the major mediator for Akt ubiquitination and activation in human lung cancer. (43) (44) (45) . We first demonstrated that TRAF4 mediates glycolysis in human lung cancer by regulating the expression of Glut1 and HK2 through Akt signaling (Fig. 7) , confirming the importance of TRAF4-mediated Akt activation in lung tumorigenesis and lung cancer metabolic reprogramming.
Overall, we demonstrated that TRAF4 regulates Akt ubiquitination and activation, and plays a critical role in human lung carcinogenesis. TRAF4 is overexpressed in human lung cancer and is essential for lung cancer cells to sustain tumorigenic properties, such as colony formation, glycolysis and xenograft tumor growth. These results suggest that TRAF4 a good molecular target for human lung cancer prevention and treatment. 
